Cargando…
Cancer immunotherapies: advances and bottlenecks
Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immu...
Autores principales: | Rui, Rui, Zhou, Liqun, He, Shiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484345/ https://www.ncbi.nlm.nih.gov/pubmed/37691932 http://dx.doi.org/10.3389/fimmu.2023.1212476 |
Ejemplares similares
-
Advances in the research of exosomes in renal cell carcinoma: from mechanisms to applications
por: Rui, Rui, et al.
Publicado: (2023) -
“Cold” colorectal cancer faces a bottleneck in immunotherapy
por: Liu, Jia-Liang, et al.
Publicado: (2023) -
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023) -
Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023) -
Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
por: Zhou, Huijie, et al.
Publicado: (2023)